From an industry perspective, a potential bottleneck that will need to be overcome in bringing targeted nanoparticles from the bench to the bedside is scale-up. Existing academic laboratory environments are adequate for manufacturing enough targeted nanoparticles for ongoing preclinical studies (in vitro and in vivo). However, human studies and clinical use will require far greater quantity of targeted nanoparticles and ...more »
Voting on Ideas
Vote for your favorite ideas by clicking on the up arrow.To undo an upvote, simply click the arrow again. This second click removes your vote.